💊Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy 20171107 💊 Tuesday November 7th, 2017By Tokio X'press Soverign
💊Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC) Tuesday November 7th, 2017By Tokio X'press Cancer, FDA Opdivo
🔬Exclusive Global License for New Method of iPS Cell Production Obtained Tuesday November 7th, 2017By Tokio X'press bio, Pharmaceutical takara-bio
📡Fujitsu Launches Field Trial of Ultra High-Density Distributed Antenna Systems for 5G 2017年11月7日 Tuesday November 7th, 2017By Tokio X'press 5G, Communication fujitsu
🎗Mitsubishi Electric Introduces New Edge-computing Software and Products Tuesday November 7th, 2017By Tokio X'press IOT mitsubishi electric
